Jang-Yang Chang

national health research institutes

H指数:56

被引数:8,948

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

BDNF Val66Met protects oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer

BDNF Val66Met可保护结直肠癌患者免受奥沙利铂诱导的周围神经病变的影响。

Science Translational Medicine

IF14.6

2026-02-180

PRE

EGFRvIII-driven microenvironmental fibroblast activation and transformation accelerate oral cancer progression via lipocalin-2/STAT3 axis

EGFRvIII驱动的微环境成纤维细胞激活和转化通过lipocalin-2/STAT3轴加速口腔癌进展

Neoplasia

IF7.7

2025-06-040

PRE

Tumor cell-derived ISG15 promotes fibroblast recruitment in oral squamous cell carcinoma via CD11a-dependent glycolytic reprogramming

ONCOGENESIS

IF6.4

2025-03-110

OAAI

Upregulation of Cathepsin S Expression Contributes to Neuronal Damage Following Kainic Acid-Induced Status Epilepticus

卡赫斯平S表达的上调加剧了海人酸诱导的癫痫持续状态后的神经元损伤

JOURNAL OF NEUROCHEMISTRY

IF4

2025-03-050

PRE

Macrophage-mediated controlled release of cysteine protease inhibitor from PLGA-PEG/hydroxyapatite microspheres for targeting cathepsin S in Alzheimer's disease

EUROPEAN POLYMER JOURNAL

IF6.3

2024-06-011

PRE

Targeting cathepsin S promotes activation of OLF1-BDNF/TrkB axis to enhance cognitive function

JOURNAL OF BIOMEDICAL SCIENCE

IF12.1

2024-05-091

OAAI

Lysosomal-targeted doxorubicin delivery using RBC-derived vesicles to overcome drug-resistant cancer through mitochondrial-dependent cell death

使用RBC衍生的囊泡通过线粒体依赖性细胞死亡克服耐药性癌症的溶酶体靶向阿霉素递送

PHARMACOLOGICAL RESEARCH

IF10.5

2023-11-012

OAAI

A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Alpelisib联合西妥昔单抗治疗复发或转移性头颈部鳞状细胞癌的1b/2期研究

TARGETED ONCOLOGY

IF4

2023-10-257

OAAI

Sprague Dawley rats from different vendors vary in the modulation of prepulse inhibition of startle (PPI) by dopamine, acetylcholine, and glutamate drugs

PSYCHOPHARMACOLOGY

IF3.3

2023-08-143

OAAI

Cathepsin S mediates interleukin 7 to sculpture the tumor immunity in head and neck cancer

CANCER RESEARCH

IF16.6

2023-04-040

PRE

MiR-455-5p suppresses PDZK1IP1 to promote the motility of oral squamous cell carcinoma and accelerate clinical cancer invasion by regulating partial epithelial-to-mesenchymal transition

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

IF12.8

2023-02-0311

OAAI

Lee et al. The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b. Pharmaceutics (vol 14, 1511, 2022)

PHARMACEUTICS

IF5.5

2023-01-190

OAAI

The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b

PHARMACEUTICS

IF5.5

2022-07-212

OAAI

Lon upregulation contributes to cisplatin resistance by triggering NCLX-mediated mitochondrial Ca2+ release in cancer cells

CELL DEATH & DISEASE

IF9.6

2022-03-1615

OAAI

Discovery of Potential Neuroprotective Agents against Paclitaxel-Induced Peripheral Neuropathy

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2022-03-028

OAAI

Identification of Prognostic Biomarkers Originating From the Tumor Stroma of Betel Quid-Associated Oral Cancer Tissues

FRONTIERS IN ONCOLOGY

IF3.3

2021-11-166

OAAI

Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors

SCIENTIFIC REPORTS

IF3.9

2021-03-012

OAAI

Ephrin A4-ephrin receptor A10 signaling promotes cell migration and spheroid formation by upregulating NANOG expression in oral squamous cell carcinoma cells

SCIENTIFIC REPORTS

IF3.9

2021-01-1212

OAAI

Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy

THERANOSTICS

IF13.3

2021-01-0113

OAAI

c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activation

THERANOSTICS

IF13.3

2021-01-0168

OAAI

Jang-Yang Chang

个人简介

教育背景

工作经历

荣誉奖项

研究方向